This effect is reinforced by the fact that treatment with the GPR55 antagonist CID16020046 significantly reduced the expression of pro-inflammatory cytokines and inhibited leukocyte activation and accumulation, which are characteristic features of IBD (90). This evidence concerns the gene GPR55 and inflammatory bowel disease.